RE: Still need for testing13 Aug 2021 10:05
I made this point recently. I see the global market as very big and a great opportunity specifically for Avacta:
In terms of vaccines, we need top up jabs. Why, because the current double vaccinated efficacy drops over time. Secondly, we can't stop new variants and we can't achieve herd immunity. That leads us to an unfortunate situation of us having to live with the virus for a long time to come. In terms of medication, I can only see 2 potential therapies that are effective and even they are to be used at specific stages of infection. This leaves the issue of controlling spread and outbreaks. Once you see beyond the noise of this and other bulletin boards, you will realise that the testing party is only getting started.
What you will find at this stage is that the regulations will get tighter and the best tests will survive. There is a a very big market still available and Avacta and **some** other stocks will pull through. Unlike in technology sector where betamax lost out to vhs OR Apple lost to Microsoft, in healthcare the winner will be the best tests and the best medication.